Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketorolac in Stanford Type A Aortic Dissection
NCT06968806Phase 3Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in aortic dissection comparing Ketorolac Group with Placebo Group (2 arms). Primary endpoint: Composite clinical endpoints at 1 year. Started Oct 2025; status: recruiting.
02
Drugs
ketorolac
03
Conditions
aortic dissection
Beyond the preview
Go deeper on NCT06968806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06968806.